Jounce Therapeutics announced that data from its Phase 1/2 ICONIC trial, an open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be the subject of two poster presentations at the upcoming American Association for Cancer Research, or AACR, meeting. In addition, Jounce Therapeutics will present a poster that will describe the preclinical evaluation of JTX-8064, a highly specific monoclonal antibody that aims to reprogram human macrophages from an immune suppressive to immune active state by inhibiting the cell surface receptor LILRB2.
https://thefly.com/landingPageNews.php?id=2871697
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.